Tuberculosis (TB) is a major cause of morbidity and mortality in women of childbearing age (15 to 44 years), accounting for almost 400,000 deaths in this age group every year. Pregnancy and HIV co-infection increase the likelihood that women with latent TB infection (LTBI) will progress to active TB disease, which raises the risk of poor maternal and infant outcomes. International guidelines
differ on the optimal regimen and dosing for TB treatment during pregnancy and postpartum in part because safety, tolerability, and pharmacokinetic (PK) data for many TB drugs are lacking in pregnant and postpartum women. This knowledge gap is of particular concern for women being treated for both TB and HIV infection and disease, who face overlapping drug toxicities and drug interactions between
TB and antiretroviral drugs. Promising new TB drugs have recently entered clinical development or have already been approved for use in non-pregnant adults, but currently there are no planned trials for any of these new agents in pregnant women. In this talk, I will highlight the management of TB during pregnancy including 1) the current knowledge and gaps regarding use of current and new antimycobacterial drugs during pregnancy as well as how pregnancy impacts the pharmacokinetics of anti-TB drugs and antiretroviral drugs; 2) how to manage antiretroviral therapy together with TB treatment during pregnancy; and 3) highlight new information about prevention of TB and unique aspects of treatment for latent TB infection that must be considered during pregnancy.